Publication year: 2012
Source: Autoimmunity Reviews, Available online 22 February 2012
M.Mahler, K.Miyachi, C.Peebles, M.J.Fritzler
Autoantibodies targeting proliferating cell nuclear antigen (PCNA) were first described over 30years ago and are historically most commonly associated with systemic lupus erythematosus (SLE). The primary antigenic target is a 34kDa protein that is part of the DNA polymerase delta multi-protein complex. A number of diagnostic platforms have incorporated PCNA into their diagnostic assays and algorithms. However, little is known about the clinical utility of autoantibodies to PCNA, especially with novel detection systems. This review will focus on the history of the discovery of the PCNA autoantigen and the current status of the diagnostic significance of anti-PCNA and suggest future studies that are required to strengthen our understanding of their clinical utility.
المواضيع المتشابهه:
- Significance of the Correlation Between the Expression of Interleukin 6 and Clinical Features in Patients With Non-Small-Cell Lung Cancer
- Significance of the Correlation Between the Expression of Interleukin 6 and Clinical Features in Patients With Non-Small-Cell Lung Cancer
- Significance of the Correlation Between the Expression of Interleukin 6 and Clinical Features in Patients With Non-Small-Cell Lung Cancer
- Clinical significance of micrometastases in lymph nodes from laryngeal squamous cell carcinoma
- Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific- pancreatic autoantibodies


رد مع اقتباس